Pharsight

Verrica Pharms patents expiration

1. Ycanth patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11052064 VERRICA PHARMS Compositions, methods and systems for the treatment of cutaneous disorders
May, 2035

(11 years from now)

US11147790 VERRICA PHARMS Treatment of cutaneous disorders
Aug, 2038

(14 years from now)

Drugs and Companies using CANTHARIDIN ingredient

Market Authorisation Date: 21 July, 2023

Treatment: Topical delivery of a cantharidin formulation to adult and pediatric patients 2 years of age and older for treating molluscum contagiosum; Topical treatment of molluscum contagiosum in adult and pedia...

Dosage: SOLUTION;TOPICAL

More Information on Dosage

YCANTH family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic